Prevalence, Specificity and Risk of Red Blood Cell Alloantibodies Among Hospitalised Hubei Han Chinese Patients

Overview

Journal Blood Transfus

Specialty Hematology

Date 2013 Dec 17

PMID 24333071

Citations 5

Authors

Pu Xu

Yan Li

Hua Yu

Affiliations

Soon will be listed here.

Abstract

Background: The prevalence, specificity and risk of red blood cell alloantibodies vary widely among different geographic areas, races, and diseases and according to different methods of study, but no data are available on the Chinese Han population, who were investigated in the present study.

Materials And Methods: Antibody screening was conducted among 42,517 hospitalised Hubei Han Chinese individuals using column agglutination technology. Samples that were positive in antibody screening were subjected to antibody identification by the tube test. Clinical data, including gender, age, race, transfusion history and records of alloantibody detection, transfusion reactions or haemolytic disease of the newborn, were collected to analyse the prevalence and specificity of alloantibodies and complications associated with them.

Results: A total of 212 patients with alloantibodies were identified among 42,517 patients, yielding a prevalence of 0.50% in this study. Significantly different prevalence rates were observed according to age and sex. The most frequently identified alloantibodies were anti-E (87/212, 41.0%), anti-D (45/212, 21.2%), anti-M (41/212, 19.3%) and a combination of anti-E and anti-c (13/212, 6.1%). Haemolytic disease was observed in 13 infants with anti-D, three infants with anti-E and one infant with anti-Fy(a) alloantibodies. Delayed haemolytic transfusion reactions occurred in four patients with alloantibodies.

Discussion: In hospitalised Hubei Han Chinese individuals, the overall prevalence of alloantibodies was 0.50%, with anti-E, anti-D and anti-M being the most frequently identified alloantibodies. These results indicate that anti-D and anti-E alloantibodies were major risk factors for haemolytic disease of the newborn or delayed haemolytic transfusion reactions in this study population.

Citing Articles

Assessment of erythrocyte alloimmunization among patients treated at a Brazilian university hospital.

Contelli H, Oliveira M, Ido A, Francalanci E, Terra P, Filho E Hematol Transfus Cell Ther. 2024; 46 Suppl 5:S128-S135.

PMID: 39261147 PMC: 11670643. DOI: 10.1016/j.htct.2024.04.128.

Investigating the Correlation Between HLA-II Gene Polymorphism and RhE Alloimmunization in Pregnant Chinese Women.

Shang W, Ou G, Ji X, Chen J, Wang J, Jiang Y Indian J Hematol Blood Transfus. 2023; 39(4):662-669.

PMID: 37786831 PMC: 10542046. DOI: 10.1007/s12288-023-01632-7.

A voluntary transfusion recipient registry in Korea as a database for blood group antibodies.

Shin D, Hong Y, Hyun J, Song E, Park K Blood Transfus. 2023; 22(4):283-291.

PMID: 37458718 PMC: 11251832. DOI: 10.2450/BloodTransfus.429.

Red blood cell alloimmunization among hospitalized patients: transfusion reactions and low alloantibody identification rate.

Pessoni L, Ferreira M, Silva J, Alcantara K Hematol Transfus Cell Ther. 2018; 40(4):326-331.

PMID: 30370410 PMC: 6200715. DOI: 10.1016/j.htct.2018.04.001.

Presence of Irregular Antibody (Anti-c) in a Multitransfused Cardiac Surgery Patient.

Mallhi R, Dimri U, Jayamanna D, Philip J Indian J Hematol Blood Transfus. 2015; 31(3):385-6.

PMID: 26085726 PMC: 4465516. DOI: 10.1007/s12288-014-0469-y.

References

Lee C, Ma E, Tang M, Lam C, Lin C, Chan L . Prevalence and specificity of clinically significant red cell alloantibodies in Chinese women during pregnancy--a review of cases from 1997 to 2001. Transfus Med. 2003; 13(4):227-31. DOI: 10.1046/j.1365-3148.2003.00445.x. View

Yazdanbakhsh K, Ware R, Noizat-Pirenne F . Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012; 120(3):528-37. PMC: 3401213. DOI: 10.1182/blood-2011-11-327361. View

Flegel W . Molecular genetics of RH and its clinical application. Transfus Clin Biol. 2006; 13(1-2):4-12. DOI: 10.1016/j.tracli.2006.02.011. View

Tormey C, Fisk J, Stack G . Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion. 2008; 48(10):2069-76. DOI: 10.1111/j.1537-2995.2008.01815.x. View

Wang Q, Yang Q, Bai Y, Zhang C, Diao Y, Fang D . Frequency of RBC Alloantibodies in Chinese Surgical Patients. Transfus Med Hemother. 2012; 39(4):283-286. PMC: 3434327. DOI: 10.1159/000339811. View

Chadebech P, Habibi A, Nzouakou R, Bachir D, Meunier-Costes N, Bonin P . Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion. 2009; 49(9):1785-92. DOI: 10.1111/j.1537-2995.2009.02199.x. View

Pahuja S, Gupta S, Pujani M, Jain M . The prevalence of irregular erythrocyte antibodies among antenatal women in Delhi. Blood Transfus. 2011; 9(4):388-93. PMC: 3200407. DOI: 10.2450/2011.0050-10. View

Hoeltge G, Domen R, Rybicki L, Schaffer P . Multiple red cell transfusions and alloimmunization. Experience with 6996 antibodies detected in a total of 159,262 patients from 1985 to 1993. Arch Pathol Lab Med. 1995; 119(1):42-5. View

Singer S, Wu V, Mignacca R, Kuypers F, Morel P, Vichinsky E . Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly asian descent. Blood. 2000; 96(10):3369-73. View

10.

Wu B, Yao D, Rong R . [Specificity and clinical features of erythrocytic allo-antibodies in hospitalized patients]. Zhonghua Yi Xue Za Zhi. 2011; 91(24):1691-3. View

11.

Nadarajan V, Laing A, Saad S, Usin M . Prevalence and specificity of red-blood-cell antibodies in a multiethnic South and East Asian patient population and influence of using novel MUT+Mur+ kodecytes on its detection. Vox Sang. 2011; 102(1):65-71. DOI: 10.1111/j.1423-0410.2011.01507.x. View

12.

Patel S, Smith N, Kapp L, Zimring J . Mechanisms of alloimmunization and subsequent bone marrow transplantation rejection induced by platelet transfusion in a murine model. Am J Transplant. 2012; 12(5):1102-12. PMC: 4296674. DOI: 10.1111/j.1600-6143.2011.03959.x. View

13.

Westhoff C, Vege S, Halter-Hipsky C, Whorley T, Hue-Roye K, Lomas-Francis C . DIIIa and DIII Type 5 are encoded by the same allele and are associated with altered RHCE*ce alleles: clinical implications. Transfusion. 2010; 50(6):1303-11. PMC: 2908519. DOI: 10.1111/j.1537-2995.2009.02573.x. View

14.

Shao C, Qin J, Sun G, Xu H, Ma L . [An analysis of RHD zygosity of Rh(D)-positive Chinese Han population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2011; 28(1):29-32. DOI: 10.3760/cma.j.issn.1003-9406.2011.01.007. View

15.

Cox J, Steane E, Cunningham G, Frenkel E . Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med. 1988; 148(11):2485-9. View

16.

Tondon R, Kataria R, Chaudhry R . Anti-M: Report of two cases and review of literature. Asian J Transfus Sci. 2009; 2(2):81-3. PMC: 2798772. DOI: 10.4103/0973-6247.42695. View

17.

Tournamille C, Meunier-Costes N, Costes B, Martret J, Barrault A, Gauthier P . Partial C antigen in sickle cell disease patients: clinical relevance and prevention of alloimmunization. Transfusion. 2009; 50(1):13-9. DOI: 10.1111/j.1537-2995.2009.02382.x. View

18.

SPIELMANN W, Seidl S . Prevalence of irregular red cell antibodies and their significance in blood transfusion and antenatal care. Vox Sang. 1974; 26(6):551-9. DOI: 10.1111/j.1423-0410.1974.tb02731.x. View

19.

Roberts I . The changing face of haemolytic disease of the newborn. Early Hum Dev. 2008; 84(8):515-23. DOI: 10.1016/j.earlhumdev.2008.06.005. View

20.

Levine P, Vogel P, Katzin E, Burnham L . PATHOGENESIS OF ERYTHROBLASTOSIS FETALIS: STATISTICAL EVIDENCE. Science. 1941; 94(2442):371-2. DOI: 10.1126/science.94.2442.371. View